Levosimendan
Levosimendan (INN) /ˌliːvoʊsaɪˈmɛndən/ is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. It is marketed under the trade name Simdax (Orion Corporation).

This is an excerpt from the article Levosimendan from the Wikipedia free encyclopedia. A list of authors is available at Wikipedia.
The article Levosimendan at en.wikipedia.org was accessed 2,375 times in the last 30 days. (as of: 07/04/2014)
Images on Levosimendan
Preview image:
Original:
Search results from Google and Bing
1
1
1
Levosimendan - Wikipedia, the free encyclopedia
Levosimendan (INN) /ˌliːvoʊsaɪˈmɛndən/ is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. It is marketed ...
en.wikipedia.org/wiki/Levosimendan
3
4
2
Clinical pharmacology of levosimendan.
Levosimendan has been developed for the treatment of decompensated heart ... The pharmacokinetics of Levosimendan are linear at the therapeutic dose range ...
www.ncbi.nlm.nih.gov/pubmed/17596101
9
7
3
REVIVE II and SURVIVE: Use of…
Two large prospective trials that evaluated the efficacy of Levosimendan in patients hospitalized for acute decompensated heart failure (ADHF) have concluded that ...
www.medscape.org/viewarticle/523043
2
>30
4
IV Levosimendan Mixed Blessing for Outpatients - MedPage Today
May 30, 2013 ... LISBON -- Repeated doses of IV Levosimendan given to outpatients with end- stage heart failure failed to improve functional capacity or quality ...
www.medpagetoday.com/MeetingCoverage/HFC/39470
4
>30
5
Levosimendan - Medscape
Levosimendan is a calcium sensitiser that can be administered intravenously (IV) to patients with acute decompensated congestive heart failure (CHF).
www.medscape.com/viewarticle/406544
5
>30
6
Is levosimendan better than dobutamine in acute heart failure in ...
Levosimendan is an inotropic agent approved in some countries for the treatment of acute heart failure (AHF).1 In 2003, Sweden was one of the first countries to ...
eurjhf.oxfordjournals.org/content/12/4/313.full
6
>30
7
Effect of Levosimendan on the Short-Term Clinical ... - Onlinejacc.org
Background This study evaluated the efficacy and safety of Levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with ...
heartfailure.onlinejacc.org/article.aspx?articleID=1671253
7
>30
8
Levosimendan in End-Stage Heart Failure - Onlinejacc.org
(2) on Levosimendan for acute heart failure. The tantalizing signal of symptomatic relief is somewhat tempered by the increased incidence of hypotension, ...
heartfailure.onlinejacc.org/article.aspx?articleid=1724966
8
>30
9
Acute hemodynamic and clinical effects of levosimendan in patients ...
Abstract. Background—We determined the short-term hemodynamic and clinical effects of Levosimendan, a novel calcium-sensitizing agent, in patients with ...
circ.ahajournals.org/content/102/18/2222.abstract
10
>30
10
DrugBank: Levosimendan (DB00922)
Jun 13, 2005 ... Levosimendan is a calcium sensitiser used in the management of acutely decompensated congestive heart failure. It increases the sensitivity of ...
www.drugbank.ca/drugs/DB00922
Search results for "Levosimendan"
Google: approx. 139.000
Levosimendan in science
Acute hemodynamic and clinical effects of levosimendan in patients ...
From the Cardiomyopathy Program and Cardiovascular Medicine Section, Boston University Medical Center (W.S.C.) and VA Boston Healthcare System ( M.T.S.) ...
Levosimendan Studies Finally Published - Medscape
Apr 8, 2013 ... REVIVEd in Print: REVIVE Levosimendan Trials Finally Get ... REVIVE investigator Dr Milton Packer (University of Texas Southwestern, Dallas).
IV Levosimendan Mixed Blessing for Outpatients - MedPage Today
May 30, 2013 ... LISBON -- Repeated doses of IV Levosimendan given to outpatients with ... Associate Clinical Professor of Medicine, University of California, ...
Effect of Levosimendan on the Short-Term Clinical ... - Onlinejacc.org
Background This study evaluated the efficacy and safety of Levosimendan, a positive inotropic drug with vasodilator effects, given intravenously to patients with ...
Levosimendan in the treatment of AHF: lessons from surveys and ...
3Heart Failure Unit, University Hospital of Coimbra Coimbra, Portugal ... However , the percentage of patients who received Levosimendan in these surveys was ...
Levosimendan: a decade of experience in Europe built on years of ...
12nd Department of Cardiology and Heart Failure Unit, University of Athens Medical ... accumulated regarding the use of Levosimendan over the last 10 years , ...
Oral levosimendan in patients with severe chronic heart failure—The ...
Division of Cardiology, Helsinki University Central Hospital, Helsinki, Finland, ... Abstract. Background: Intravenous Levosimendan improves symptoms in acutely  ...
Safety and efficacy of a novel calcium sensitizer, levosimendan, in ...
Aims To evaluate the safety and efficacy of Levosimendan in patients with left ventricular failure complicating acute .... Oxford Journals Oxford University Press.
Levosimendan reduces heart failure after cardiac surgery: a ...
Department of Anesthesiology and Intensive Care, Kuopio University Hospital, ... OBJECTIVE: To investigate whether Levosimendan diminishes the incidence of ...
Intravenous levosimendan … - University of Gothenburg, Sweden
Intravenous Levosimendan vs. dobutamine in acute decompensated heart failure patients on beta-blockers. Scientific journal article - peer reviewed. Read the ...
Books on the term Levosimendan
Intensive Care Medicine: Annual Update 2009
Intensive Care Medicine: Annual Update 2009
Jean-Louis Vincent, 2010
Dubin A, Murias G, Sottile JP, et al (2007) Effects of Levosimendan and dobutamine in experimental acute endotoxemia: a preliminary controlled study. Intensive Care Med 33: 485–494 43. Zager RA, Johnson AC, Lund S, Hanson SY , Abrass ...
Case-Based Anesthesia: Clinical Learning Guides
Case-Based Anesthesia: Clinical Learning Guides
George Shorten, Stephen F. Dierdorf, Gabriella Iohom, 2012
The deteriorating renal function prompted the second intensivist to change from dobutamine to Levosimendan in the patient discussed in this case. In the setting of acute heart failure, Levosimendan is the most widely studied inotrope to date.
Levosimendan: Webster's Timeline History, 1994 - 2007
Levosimendan: Webster's Timeline History, 1994 - 2007
Icon Group International, 2010
Webster's timelines cover bibliographic citations, patented inventions, as well as non-conventional and alternative meanings which capture ambiguities in usage. These furthermore cover all parts of speech (possessive, institutional usage, geographic usage) and contexts, including pop culture, the arts, social sciences (linguistics, history, ge...
Recent Advances in Anaesthesia and Intensive Care
Recent Advances in Anaesthesia and Intensive Care
Cashman/Grounds
This energy-dependent process involves increasing the intracellular concentration of cyclic adenosine monophosphate (cAMP).1 Levosimendan has a dual mechanism of action, acting as a positive inotrope and a vasodilator. The positive ...
Pediatric Critical Care Medicine
Pediatric Critical Care Medicine
Anthony D. Slonim, Murray M. Pollack, 2006
Levosimendan represents the first of an entirely new class of agents, calcium sensitizers, that enhance the sensitivity of the myofilament to calcium without an increase in cytoso- lic calcium levels. Contraction of cardiac myofilaments is ...
Oxford Desk Reference: Critical Care
Oxford Desk Reference: Critical Care
Carl Waldmann, Neil Soni, Andrew Rhodes, 2008
The most studied calcium sensitizer, Levosimendan, has recently been introduced in many countries for the treatment of acutely decompensated chronic heart failure (HF) and has both positive inotropic and vasodilatatory effects. It differs from ...
Development of Google searches


Blog posts on the term
Levosimendan
Oxygen Biotherapeutics Inc Closes the Acquisition
Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimendan; John Kelley Appointed CEO of Oxygen Biotherapeutics
www.biospace.com/news_story.aspx?NewsEntityId=315701
Levosimendan in newborns - cardiovascular problems - 99nicu - the community for professionals in neonatal medicine
Levosimendan in newborns - posted in cardiovascular problems: Hi all: I would ask if anyone has experience treating cardiogenic shock or heart failure in infants with Levosimendan. Sincerely, Dr. Fernando Agama C. Unidad de Neonatología Hospital Dr. Enrique Garcés Quito-Ecuador
99nicu.org/forum/index.php?/topic/1370-levosimendan-in-newborns/
(OXBT) and Phyxius Pharma, New Evidence on Levosimendan in Heart Surgery Patients | Trader Power
traderpower.com/oxbt-and-phyxius-pharma-new-evidence-on-levosimendan-in-heart-surgery-patients/
Oxygen Biotherapeutics Up +57.48% On Levosimendan Possibilities (NASDAQ:OXBT)
Oxygen Biotherapeutics, Inc. (NASDAQ:OXBT) As the Nasdaq begins to make a turn for the better, I would like to direct your attention to Oxygen Biotherapeutics (www.
nestleadams.edublogs.org/2013/11/05/oxygen-biotherapeutics-up-57-48-on-levosimendan-possibilities-nasdaqoxbt/
UPDATE: Oxygen Biotherapeutics Reports Deal to Buy Phase 3, FDA Fast-Track Designated Levosimendan from Phyxius Pharma | Benzinga
www.benzinga.com/news/13/10/4008200/update-oxygen-biotherapeutics-reports-deal-to-buy-phase-3-fda-fast-track-designat
Levosimendan improves event free survival by 50 percent in end-stage heart failure | Science Codex
Lisbon, 27 May 2013: Ambulatory Levosimendan improves event free survival by 50% compared to placebo, according to results from the LevoRep Study presented today during the late breaking trial session1 of the Heart Failure Congress 2013. In a second
www.sciencecodex.com/levosimendan_improves_event_free_survival_by_50_percent_in_endstage_heart_failure-112871
Oxygen Biotherapeutics Up 48.67% on Presumed Levosimendan Published Findings (NASDAQ:OXBT) | MicroCaPicks
Served fresh daily
microcapicks.com/oxygen-biotherapeutics-up-48-67-on-presumed-levosimendan-published-findings-nasdaqoxbt/
Oxygen Biotherapeutics Closes the Acquisition of Phyxius Pharma Assets Related to Levosimenda | SEBIO News
sebio.org/2013/11/15/oxygen-biotherapeutics-closes-the-acquisition-of-phyxius-pharma-assets-related-to-levosimenda/
Critical Care | Full text | Levosimendan and mortality after coronary revascularisation: a meta-analysis of randomised controlled trials
Patients undergoing coronary revascularization often require inotropic support that has been associated with an increased risk for death and morbidity. The purpose of this study was to evaluate the effect of Levosimendan versus control on survival after coronary revascularization.
ccforum.com/content/15/3/r140
Critical Care | Full text | Levosimendan may improve survival in patients requiring mechanical assist devices for post-cardiotomy heart failure
Most case series suggest that less than half of the patients receiving a mechanical cardiac assist device as a bridge to recovery due to severe post-cardiotomy heart failure survive to hospital discharge. Levosimendan is the only inotropic substance known to improve medium term survival in patients suffering from severe heart failure.
ccforum.com/content/10/1/r17
123